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Abstract
Background: Our aim was to summarize and compare relevant recommendations from evidence-based CPGs (EB-CPGs).
Methods: Systematic review of clinical practice guidelines. Data sources: PubMed, EMBase, Cochrane Library, LILACS,
Tripdatabase, and additional sources. In July 2017, we searched CPGs that were published in the last 10 years, without
language restrictions, in electronic databases, and also searched specific CPG sources, reference lists, and consulted experts.
Pairs of independent reviewers selected EB-CPGs and rated their methodological quality using the AGREE-II instrument. We
summarized recommendations, its supporting evidence, and strength of recommendations according to the GRADE
methodology.
Results:We included 16 EB-CPGs out of 2262 references identified. Only nine of them had searches within the last 5 years
and seven used GRADE. The median (percentile 25–75) AGREE-II scores for rigor of development was 49% (35–76%) and the
domain “applicability” obtained the worst score 16% (9–31%). We summarized 31 risk stratification recommendations, 21.6%
of which were supported by high/moderate quality of evidence (41% of them were strong recommendations), and 16
therapeutic/preventive recommendations, 59% of which were supported by high/moderate quality of evidence (75.7%
strong). We found inconsistency in ratings of evidence level. “Guidelines’ applicability” and “monitoring” were the most
deficient domains. Only half of the EB-CPGs were updated in the past 5 years.
Conclusions:We present many strong recommendations that are ready to be considered for implementation as well as
others to be interrupted, and we reveal opportunities to improve guidelines’ quality.
Keywords: Perioperative care, Clinical practice guidelines, Systematic review, GRADE, AGREE-II
Implication statement
We identified many risk stratification and therapeutic
strong recommendations that can be implemented and
other ones usually followed by many anesthesiologists in
their daily practice that should be interrupted.
Finally, we described opportunities to improve
guidelines’ quality.
Background
An estimated 313 million major surgical procedures are
undertaken every year worldwide [1]. Low- and high-
income countries show an estimated rate of major sur-
gery of 295 and 11,110 procedures per 100,000 popula-
tion per year respectively [1], an enormous disparity for
the recommended minimum threshold of 5000 opera-
tions per 100,000 people, that is associated with desir-
able health outcomes. At current rates of surgical and
population growth, 6.2 billion people (73% of the world’s
population) will be living in countries below the mini-
mum recommended rate of surgical care in 2035 [2].
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However, the crude number of patients who receive sur-
gery is increasing, as well as their mean age and the oc-
currence of comorbidities [3]. Because of the inherent
risks of death and complications, surgical safety is a sig-
nificant public-health concern. As examples, 2.4% (95%
CI 2.1 to 2.6%) of patients undergoing surgery will suffer
major cardiac complications [4], and 5% (95% CI 4.5 to
5.5%) will have a perioperative myocardial infarction [5].
In this context, to provide adequate preoperative care is
truly mandatory. The first routine preoperative tests
started 50 years ago with only a handful of actions and
have nowadays expanded to a large set of risk stratifica-
tion or diagnostic tests to define the preoperative clinical
risk categories and also many preventive interventions.
Lately, efforts to standardize care have been made, spe-
cially through the implementation of clinical practice
guidelines (CPGs) with recommendations useful both
for health providers and patients [6]. These recommenda-
tions usually consider all risks and benefits for a risk stratifica-
tion or therapeutic procedure to be undertaken, sometimes
even including algorithm pathways. The potential benefits, like
the safety of care and standardization of procedures, are only
as good as the quality of the practice guidelines implemented.
Unfortunately, those CPGs not supported by the best evidence
might promote inappropriate preoperative testing behaviors,
negative both for patients and health systems. For example,
false positive results, coming from inappropriate testing, may
delay or prevent surgery, thus creating unnecessary stress or
harm to patients.
Multiple medical societies and organizations around the
world have published preoperative evaluation CPGs; how-
ever, many of them are not even based on solid scientific
evidence. Additionally, not all of them harness methods
like the Grading of Recommendations Assessment, Devel-
opment, and Evaluation (GRADE) approach, which is one
of the soundest system for rating the quality of a body of
evidence in systematic reviews and CPGs [7]. GRADE of-
fers a transparent and structured process for developing
and presenting evidence summaries and making recom-
mendations [7].
A systematic review found no evidence from high
quality studies to support routine preoperative tests in
healthy adults undergoing non-cardiac surgery [8]. Risk
stratification testing based on the problems identified
during the preoperative assessment seems justified, but
there is still little evidence supporting it [8]. In this way,
the implementation of EB-CPGs may lead to a reduction
in the number of unnecessary preoperative tests, without
affecting patient safety [9–13]. The first health technol-
ogy assessment (HTA) on the topic published in 1989 by
the Swedish Council on Technology Assessment in
Health Care (SBU) [14], showed healthcare quality im-
provements and cost savings using an evidence-based
approach. The findings of this report have been
confirmed by nine other subsequent studies from five
countries, collected in another HTA document [15].
For this reason, through an overview of clinical
practice guidelines, we aimed to identify and synthetize
EB-CPGs on preoperative care that were published
worldwide in the last 10 years, in order to help
prioritization processes. We also rated CPGs’ quality and
summarized recommendations describing their level of
evidence and the strength of recommendations accord-
ing to the GRADE approach [7].
Methods
Study design We performed a systematic review (over-
view) of EB-CPGs following Cochrane methods [16] and
the Argentinean Academy of Medicine’s Guide for the
adaptation of CPGs for searching and selecting CPGs
[17]. For reporting, we followed the PRISMA statement
[18] and a specific guideline for overviews of systematic
reviews (Online supplemental material. Appendix 1.
PRISMA checklist) [19]. The protocol is available in
Spanish including a summary in English.1
We aimed to identify the most reliable CPGs; there-
fore, we used a definition for EB-CPGs previously re-
ported [20]. The inclusion eligibility criteria (all criteria
required) were as follows:
a) CPGs of perioperative care published in the last 10
years including those recommendations potentially
applicable to any kind of surgery, not site or
condition-specific
b) b) Provides a list of the CPG development panel
members including their expertise or qualifications.
c) Use standard methods such as Cochrane methods,
Equator Network-proposed checklists, or any suffi-
ciently detailed method allowing reproducibility of
the identification, data collection, and study risk of
bias assessment.
d) Report of the level of evidence that supports each
recommendation
Exclusion criteria (any criterion required) were as
follows:
a) Guidelines limited to single specific conditions such
as obesity, renal disorders, or pheochromocytoma
b) Guidelines limited to single specific body part
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c) Guidelines including some recommendations but
whose entire focus was clearly not the preoperative
care
Search strategy In July 2017, we searched CPGs pub-
lished in the last 10 years without language limitations in
main electronic databases, metasearch engines, specific
CPG sources, reference lists and consultation of experts,
and the main scientific societies related to preoperative
evaluation. The sources included PubMed, EMBase,
Cochrane Library, LILACS, Tripdatabase, and additional
sources: National Guideline Clearinghouse, NeLH Guide-
lines Finder, Guía Salud GPCs en España, GAC guidelines,
CMA Infobase: Clinical Practice Guidelines Database
(CPGs), New Zealand Guidelines, Scottish Clinical Guide-
lines, EBM Guidelines, Health Services/Technology As-
sessment Text (HSTAT), National Institute for Health
and Clinical Excellence (NICE), and Institute for Clinical
Systems Improvement (ICSI). See Online supplemental
material. Appendix 2. Search strategy for details of these
sources and our search strategy for preoperative care. The
search strategy was developed by a trained librarian, and
the citations were initially managed for deduplication
trough EndNote 9® reference manager.
Selection and data extraction Pair of reviewers inde-
pendently selected (by title and abstract first, and full
text eligible studies afterwards) the articles retrieved,
with a specific software to facilitate the initial phases of
systematic reviews called Early Review Organizing Soft-
ware (EROS) [21]. One reviewer extracted them while
the other verified the data in a previously piloted form
(which included variables such as search date, objective,
setting, target population, target professionals, recom-
mendations, classification system of the quality of evi-
dence and of the strength of the recommendation,
quality of evidence by recommendation, and the strength
of each recommendation) and preoperative clinical risk
criteria and categories (see Online supplemental material
3. Preoperative clinical risk criteria and categories).
Discrepancies were resolved by a consensus of the whole
team.
Guideline quality appraisal and classification Inde-
pendent pairs of reviewers rated each EB-CPGs using the
AGREE-II tool consisting of 23 key items organized in six
domains: scope and purpose, stakeholder involvement, rigor
of development, clarity of presentation, applicability, editorial
independence, and two overall evaluation items [22]. Each
item was graded using a scale of 7 points: from 1, meaning
“Strongly disagree,” to 7, meaning “Strongly agree.” The total
was presented as a percentage of the maximum possible
score for that domain (from 0 to 100%). We present the
AGREE-II domain scores expressed as a percentage across
CPGs (Online Supplemental material. Appendix 5 with the
explanation of each items of the AGREE-II domains). Dis-
crepancies were resolved by a consensus of the whole team.
We also categorized each EB-CPGs according to the
extent to which they successfully addressed AGREE-II
criteria as follows [17]:
Strongly recommended (++), CPG whose standardized
score exceeds 60% in ≥ 4 AGREE-II domains. The
scores of the remaining domains must be ≥ 30% and >
60% for the domain rigor of development.
Recommended (+), CPG whose standardized score
ranges from 30 to 60% in ≥ 4 AGREE-II domains. The
rigor of development score must be between 30 and 60%.
Not recommended (–), CPG whose standardized score
is < 30% in ≥ 4 AGREE-II domains or if rigor of devel-
opment score is less than 30%.
To deal with discrepancies between the direction and
strength of the CPG recommendations, we applied a rule
to decide “doing or not doing the recommendation”:
Yes (Y)–no (N) to doing it: ≥ 2/3 recommendations in
the same direction (for/against) and ≥ 2/3 strong
recommendations.
Probably yes (PY)–probably no (PN) to doing it: ≥ 2/3
recommendations in the same direction (for/against)
and < 2/3 strong recommendations.
Uncertainty (?) to do it: < 2/3 recommendations in the
same direction (for/against).
Synthesis of results We conducted a tabular synthesis
of the recommendations to describe their strength and
the level of evidence supporting them according to the
current GRADE methodology [7], and transforming the
original grading system when necessary, to compare and
integrate the results for each recommendation in a uni-
fied manner. Simply put, the GRADE quality of evidence
can be HIGH, MODERATE, LOW and VERY LOW.
The Randomized Clinical Trials (RCTs) start from
HIGH quality of evidence, and the non-randomized
studies start from a LOW quality of evidence. Five cri-
teria can downgrade one or two levels: methodological
quality (study limitations), inconsistency of results, indir-
ectness, imprecision, and publication bias. In cases
where there are no methodological limitations, there are
three criteria that can upgrade one or two levels: magni-
tude of effect, dose-response effect, and confounders
underestimating the effect. For mapping the level of
evidence to a common grading system (GRADE), we re-
assessed all evidence when the translation was not
obvious. Pair of reviewers independently extracted or
reassessed the level of evidence, and discrepancies were
resolved by a consensus of the whole team. Regarding
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the strength of a recommendation, which is defined as
the extent to which one can be confident that the desir-
able consequences of an intervention outweigh its un-
desirable consequences, GRADE uses four simple
categories to classify them. The categories are “strong”
or “weak” and “for” or “against” a certain risk stratifica-
tion or therapeutic approach. We presented descriptive




The search strategy identified 2262 references after the
elimination of duplicates. After the selection process, we
identified 23 references corresponding to 16 EB-CPGs
published in the last 10 years (Fig. 1 flowchart). Two ref-
erences were examined in depth and eventually excluded
since they only transcribed pre-existing CPGs, already
included in our selection [23, 24].
Guideline characteristics
Table 1 provides a general description of the included EB-
CPGs. Seven were developed in America (4 in the USA, 1
in Argentina, 1 in Brazil, and 1 in Canada), seven in Eur-
ope (2 continental, 2 from Italy, 1 in Belgium, 1 in
Scotland, and 1 in UK), and two were global collabora-
tions. Only 8/16 (50%) of the EB-CPGs that reported their
search date, conducted their searches within the last 5
years. Out of the EB-CPGs, ten addressed multiple
practices, five focused on unique practices, one referred to
perioperative fasting, and the remaining four were about
antimicrobial prophylaxis. Furthermore, four were risk
stratification recommendations, five were therapeutic or
preventive interventions, and six considered both aspects.
Each guideline reports the levels of evidence and the rec-
ommendation grading systems used by their authors. The
grading system used were GRADE (7 EB-CPGs), SIGN [41]
(2 EB-CPGs), and the others utilized their own or modified
systems (Online supplemental material Appendix 4).
We presented the scores as a percentage per each
AGREE-II domain. The domains with the best median
score (percentile 25–75) were editorial independence
91% (81–100), clarity of presentation 85% (69–97), and
scope and objective 80% (65–89). Stakeholder involve-
ment 53% (44–62) and rigor of development 49% (35–
76) had an intermediate performance while “applicabil-
ity” was the most deficient 16% (9–31). Regarding the
guideline recommendation category, 6/16 (37%) were
classified as highly recommended and the rest as recom-
mended (Online supplemental material Appendix 5). An
overall AGREE-II score is also presented in Table 1.
Risk stratification recommendations (diagnostic tests)
Table 2 shows the risk stratification recommendations
presenting the level of evidence and recommendation
strength of the EB-CPG with the highest overall and
methodological rigor AGREE-II score. The 31 risk strati-
fication recommendations included 102 specific
Fig. 1 Study flowchart
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NICE 2016 [25] National Institute of
Health and Care of
Excellence






ESC/ESA 2014 [26] European Society of
Cardiology/European
Society of Anesthesia




4.5 Dx, Tx 4.5
SBC 2017 [27] Brazilian Society of
Cardiology
Brazil 2016 3rd guide for the perioperative
evaluation of the Brazilian Society
of Cardiology
4.5 Dx, Tx 4.5
ACC/AHA 2014 [28] American College of
Cardiology/American
Heart Association






CCSG 2017 [29] Canadian Cardiovascular
Society
Canada 2015 Guidelines on perioperative
cardiac risk assessment and
management for patients who
undergo noncardiac surgery
3 Dx, Tx 3
ERAS Society 2012 [30] Society of post-surgical
recovery
World 2012 Guidelines for perioperative care
in elective rectal/pelvic surgery:
enhanced recovery after surgery
4 Dx, Tx 4
SARNePI 2014 [31] Italian Society of Anesthesia
and Intensive Pediatric
Therapy and Neonatology
Italy 2012 Preoperative evaluation in
infants and children:
recommendations





ICSI 2012 [32] Institute for the
Improvement of
Clinical Systems
USA 2012 Pre-operative evaluation 4 Dx, Tx 4
ERAS Society 2016 [33] Post-Surgical
Recovery Society
World 2014 Guidelines for pre- and intra-
operative care in gynecologic/
oncology surgery: enhanced
recovery after surgery
4 Dx, Tx 4
ESA 2011 [34] European Society
of Anesthesia
Europe† 2009 Perioperative fasting guide in
adults and children
4 Tx 4
BARA 2013 [35] Regional Anesthesia
Associations of Belgium




ASHP 2013 [36] American Society of
Health-System Pharmacists




SIGN 2014 [37] Scottish Intercollegiate
Guidelines Network
Scotland 2007 Antimicrobial prophylaxis in
surgery
6.5 Tx 6.5
CDC 2017 [38] Center for Disease
Control
USA 2014 Guideline for the prevention
of surgical site infections
6 Tx 6
PNLG 2009 [39] National Program of
Italian Guides
Italy NR Perioperative antibiotic
prophylaxis in adults
3 Tx 3
SAC 2016 [40] Argentine Society of
Cardiology
Argentina 2015 Argentine Consensus on
Cardiovascular Risk Assessment
in Non-Cardiac Surgery
6 Dx, Tx 6
NR not reported
*Diagnostic practice (Dx), therapeutic/preventive (Tx)
§Based on AGREE-II tool. See supplemental materials for more details
†The whole continent
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Table 2 Risk stratification, GRADE level of evidence and strength of recommendation by clinical specialties
General requirements
1. Preoperative evaluation
Pediatric patients receiving anesthesia Very low Strong for
Emergency surgeries in pediatric patients Very low Strong against
All patients who are undergoing diagnostic or therapeutic procedures Very low Weak for
Patients with ASA 1 or 2 without surgical or obstetric history (preanesthetic evaluation, including
physical examination, the day of the procedure).
Very low Weak for
Patient with significant medical, surgical, or obstetrical history (anesthesiologist assessment) Very low Weak for
In case of bleeding or complication history of previous alloimmunization, it is recommended to
evaluate the blood type.
Very low Weak for
2. Informed consent (Ideally written)
Provide information on risks and benefits related to obstetric anesthesia and analgesia. Very low Weak for
3. Complete laboratory
Patients undergoing low-risk surgery independently of their ASA score Very low Strong against
Patients undergoing intermediate-risk surgery Very low Strong against
Patients with renal or cardiovascular disease undergoing intermediate-risk surgery that has not been
recently evaluated
Very low Weak for
Patients undergoing high-risk surgery Very low Strong for
Patients with preeclampsia or other preceding or a suspect of hemostatic disorder, it is
recommended to apply platelet count, liver function test, and evaluation of coagulation
Very low Weak for
In case of bleeding or complication history of previous alloimmunization, it is recommended
to evaluate the blood type.
Very low Weak for
Patients with liver failure Very low Strong for
In anticoagulated patients (e.g., consume Warfarin) Low Strong for
Patients with potential risk of bleeding undergoing intermediate or high-risk surgery Very low Strong for
Routinely Very low Strong against
4. Hematocrit and hemoglobin
In pediatric patients with possible bleeding Low Strong for
In pediatric patients routinely perform minor surgery Low Strong against
Patients with anemia or blood disease or liver disease; when you suspected of anemia or other
chronic disease during clinical examination. In medium or high-risk surgeries, anticipated
transfusion requirement
Low Strong for
Patients requiring intermediate or major surgery, and bleeding risk of transfusion requirement Low Strong for
Patients over 40 years Low Weak for
Patients with a history of hematological or liver disease Low Strong for
5. Hemostasis/coagulation tests
Pediatric patients with negative history Low Strong against
Patients with a history of bleeding Low Strong for
Patients with liver failure Very low Strong for
In anticoagulated patients (e.g., consume Warfarin) Low Strong for
Patients with potential risk of bleeding undergoing intermediate or high-risk surgery Very low Strong for
Routinely Very low Strong against
6. Urinalysis
Routinely before surgery Very low Weak against
Urine or culture if diagnosing a urinary infection can influence surgery decisions Very low Weak for
7. Glucose
Routinely to pediatric patients Low Strong against
Diabetic patients Low Strong for
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Table 2 Risk stratification, GRADE level of evidence and strength of recommendation by clinical specialties (Continued)
8. Glycated hemoglobin (HbA1c) test
Diabetic patient without Hb1Ac within 3 months Very low Weak for
Patients without diabetes Very low Weak against
9. Assessment of risk factors for surgical site infection
Assessment of smoking, diabetes, obesity, malnutrition, and chronic skin disease Low Strong for
10. Kidney function tests
For minor surgery in ASA 1/2 patients or intermediate-risk surgery in ASA 2 patients Very low Weak against
For complex or major surgery in ASA 1 patients at risk of acute kidney injury (AKI) Very low Weak for
In intermediate-risk surgery in ASA 2 patients at risk of AKI. In patients with increased risk surgery
performed
Very low Weak for
ASA 3/4 patients: at risk of AKI in low-risk surgery or just higher-risk surgery Very low Weak for
11. Sickle cell disease/trait test
Routinely Very low Weak against
Assess personal of family history of sickle cell anemia Very low Weak against
Contact a specialized service providing treatment to a confirmed case Very low Weak for
12. Chest X-ray
Routinely in healthy people Low Strong against
Patients with a history or diagnostic tests suggesting cardiorespiratory disease Moderate Weak for
Patients over 40 years, patients undergoing non-low-risk surgery Low Weak for
Patients undergoing non-low-risk surgery or mainly intrathoracic or intraabdominal surgery Moderate Weak for
13. Pregnancy testing
Performed in women of childbearing age Very low Weak for
Test the day of surgery in women of childbearing age.
In pregnant women, ensure that surgery and anesthesia does not threaten the fetus life.
Document all discussions with women about whether to carry out a pregnancy test.
Carry out the pregnancy test under the possibility of pregnancy.
Very low Strong for
Cardiovascular requirements
14. Electrocardiography:
In neonates and/or children of 6 months Low Weak for
Healthy people undergoing minor surgery Low Strong against
Perform in cases of clinical suspicion Low Weak for
People over 65 undergoing minor or intermediate surgery Very low Strong against
People with cardiovascular disease Low Weak for
People with a morbidity undergoing intermediate or major surgery High Strong for
15. Effort electrocardiography
Patients undergoing surgeries of intermediate or high risk of complications, including arterial
vascular surgery (without severe cardiovascular perioperative conditions)
Low Weak for
Patients undergoing low-risk surgery Low Strong against
Patients undergoing intermediate-risk surgery Low Strong against
16. Resting echocardiography
High-risk surgery
Patient with suspected moderate or severe valvular involvement without evaluation in the last
year or with worsening of symptoms
Low Strong for
Patient with heart failure or symptoms suggestive of heart problems, without assessment in the
past year, undergoing cardiac surgery
Low Weak for
Symptomatic patients with stent grafts who go to surgery and who have no evaluation in the
last year
Low Strong for
Asymptomatic patients Low Weak for
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Table 2 Risk stratification, GRADE level of evidence and strength of recommendation by clinical specialties (Continued)
Low, intermediate or uncertain surgical risk
Routine test in asymptomatic patients without suspect of heart failure or severe valvular disease Very low Weak against
17. Effort echocardiography
Routinely to assess cardiac risk Low Strong against
18. Tomographic coronary angiography
Routinely to assess cardiac risk Moderate Strong against
19. Assessment of left ventricular function
Patients suspected to have valvular disease with important clinical manifestations or undergoing
liver transplantation
Low Weak for
Patients with heart failure without ventricular function assessment Low Weak against
Patients undergoing high-risk surgery Moderate Weak for
Obese patients (BMI ≥ 40) undergoing bariatric surgery Low Weak for
Routinely Moderate Strong against
20. Natriuretic peptide
Patients undergoing cardiac surgery High Weak for
Patients over 55 years with at least one cardiovascular risk factor undergoing non-cardiac surgery Low Weak for
21. Brain natriuretic peptide (BNP) or NT-proBNP
Patients over 65 years or patients between 45 and 64 years with significant cardiovascular disease
or score (revised cardiac risk index (RCRI) ≥ 1
Moderate Strong for
22. Troponin
Troponin prior to vascular surgery Moderate Weak for
Troponin as a preoperative marker of cardiovascular risk and mortality in non-cardiac surgery Low Weak for
23. Coronary angiography
The indications of angiography and coronary revascularization are those of non-surgical context Moderate Strong for
Urgent angiography in patients with myocardial infarction without ST elevation requiring elective
non-cardiac surgery or with a computed tomography (CT) with multiple cuts showing serious injury
of the left coronary trunk
Low Weak for
Urgent or early invasive strategy for patients with NSTEMI requiring elective non-cardiac surgery High Strong for
Patients with recent coronary disease at high clinical risk, functional class III-IV in the last 6 months,
or patients with severe valve disease and concomitant coronary heart disease
Low Strong for
Patients with non-high-risk criteria (Annex 5) and functional or pharmacological stress tests showing
myocardial ischemia
Low Weak against
Patients with or without stable coronary disease functional class I-II without evidence of ischemia by
stress tests, or those with severe coronary disease according CT multislice (excluding injury of left
coronary trunk) clinically stable without ischemia, or in patients whose non-cardiac surgery cannot
be delayed more than 2 weeks due to the underlying disease
Low Strong against
24. Noninvasive test for myocardial ischemia
Patients undergoing intermediate or high-risk surgery (without severe cardiovascular perioperative
conditions) and those undergoing arterial vascular surgery
Moderate Weak for
Intermediate or high-risk patients with poor functional capacity undergoing intermediate-risk surgery Moderate Weak against
Patients undergoing low-risk surgery Low Strong against
Low-risk patients undergoing low or intermediate-risk surgery Low Strong against
Pulmonary requirements
25. Polysomnography
In patients requiring continuous positive airway pressure (CPAP) High Strong for
Patients presumed to have obstructive sleep apnea (OSA) based on the preoperative history
and physical examination
Low Weak for
26. Lung function tests
Spirometry in patients undergoing non-high-risk surgery Very low Strong against
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recommendations according to the population/prob-
lem or the type of surgery. Out of the 102 recom-
mendations, 5 (4.9%) had a high level of evidence,
17 (16.7%) had a moderate level, 45 (44.1%) had a
low level, and 35 (34.3%) had a very low/insufficient
level. Regarding recommendation strength, 24
(23.5%) were strong for, 26 (25.5%) were strong
against, 37 (36.3%) weak for, and 15 (14.7%) were
weak against.
We found discrepancies among EB-CPG in 10 out of
102 (10%) risk stratification recommendations After ap-
plying the rule “doing or not doing the recommenda-
tion,” 31 (60 specific) are “doing” and 31 are (39 specific)
“not doing” diagnostic evaluations (see Online supple-
mental material Appendix 6. Table 1 GRADE level of
evidence and strength of recommendations by CPG;
Table 2 Recommended risk stratification evaluations
only and Table 3 Not recommended risk stratification
evaluations to facilitate the finding of relevant recom-
mendation by different point of access).
Therapeutic/preventive recommendations
Table 3 shows the therapeutic/preventive recommenda-
tions using the same presenting criterion in Table 2.
The 16 therapeutic/preventive recommendations in-
cluded 78 specific recommendations according to the
Table 2 Risk stratification, GRADE level of evidence and strength of recommendation by clinical specialties (Continued)
Arterial blood gas analysis in patients undergoing non-high-risk surgery Very low Strong against
Assessment by medical senior anesthesiologist after confirming respiratory illness or suspected
in patients ASA 3/4 undergoing high-risk surgery
Very low Weak for
High risk surgery requirements
27. Stress testing
In high-risk patients with unknown functional capacity Moderate Weak against
Patients with major criteria of high cardiovascular risk (Annex 5) Low Strong against
For high-risk patients and moderate to good (≥ 4 METs to 10 METs) functional capacity Low Weak against
For high-risk patients and poor (< 4 METs) or unknown functional capacity, if it will change
management.
Low Weak against
Patients with low risk and a poor (< 4METs) or unknown functional capacity, who have angina
or dyspnea functional class I-II
Low Weak for
Patients with low clinical risk criteria established in Annex 5, who are asymptomatic and with
good functional class
Low Weak against
Routinely for patients undergoing low-risk noncardiac surgery Moderate Strong against
28. Stress test image
For high-risk surgery patients with two or more clinical risk factors and low functional capacity Low Strong for
For intermediate and high-risk patients with one or two clinical risk factors and poor functional
capacity (< 4MET)
Very Low Weak against
For low-risk patients regardless of the clinical state of patient Very low Strong against
Special situations or considerations
29. Cardiopulmonary stress test
Cardiopulmonary exercise testing to improve the estimation of cardiac risk Low Strong against
High-risk patients with unknown functional capacity Moderate Weak against
30. Pharmacological stress test
Patients undergoing non-cardiac surgery who have poor functional capacity (< 4 METS) dobutamine
stress test
Moderate Weak for
Routinely in asymptomatic patients who are at low-risk surgery Moderate Strong against
31. Prokinetic and other interventions
Routine use of antacids, metoclopramide, or H2-receptor antagonists before elective surgery in
non-obstetric patients
High Strong against
H2-receptor antagonists the night before and the morning of elective cesarean section Moderate Strong for
Intravenous H2-receptor antagonist before emergency cesarean section; supplemented with 30ml
of sodium citrate if general anesthesia is planned
Moderate Strong for
The presented level of evidence and recommendation strength comes from the EB-CPG with the highest overall and methodological rigor AGREE-II score. The
level of evidence and recommendation strength by EB-CPG is presented in the online supplemental material 6.a
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Smoking cessation advice Low Strong for
2. Fast
Stop fluid intake in children and adults at least 2 h before elective surgery in Moderate Strong for
Stop intake of solids in children and adults 6 h before surgery Moderate
Stop intake in infants up to 4 h before surgery and 6 h in those who consume other milk Low
Intake of clear fluids (including water, clear juice, and tea or coffee without milk) in children
and adults up to 2 h before elective surgery.
Moderate
3. Carbohydrate intake
Intake until 2 h before surgery in nondiabetics Moderate Strong for
Taking high carbohydrate drinks to 2 h before elective surgery even in diabetic patients High
Drinking liquids rich in carbohydrates before elective surgery improves subjective well-being,
reduces thirst and hunger and reduces postoperative insulin resistance
High
4. Alcohol intake
Avoid drinking 4 weeks before, especially in rectal surgery. Moderate Strong for
5. Bowel preparation (cleansing)
With or without planned bowel resection Moderate Strong against
6. Antimicrobial prophylaxis (see Annex 2 for specific antibiotic recommendation details)
Antibiotics intravenous (first generation cephalosporin or amoxicillin/clavulanate) routinely 60 min
before the incision. Further doses for prolonged surgery, severe blood losses and obese patients
Low Weak for
Vancomycin monotherapy Low Weak against
For insertion of a pacemaker or cardiac defibrillator, in open surgery including coronary bypass
and valve prosthesis placement
High Strong for
For lung resection Moderate Strong for
For clean-contaminated head and neck surgery High Strong for
For adenotonsillectomy High Weak against
For ear surgery including myringoplasty High Strong against
For nasal and paranasal sinus surgeries Moderate Strong against
For clean head and neck surgery Very low Strong against
For colorectal surgery High Strong for
For oncological breast surgery and reduction mammoplasty High Strong for
For endoscopic gastrostomy and stomach and duodenum surgery Moderate Strong for
For clean-contaminated procedures esophagus and small intestine Very low Weak for
For appendectomy, open biliary surgery, liver resection surgery, pancreatic surgery, breast augmentation High Strong for
For inguinal hernia repair with or without use of prosthetic material, laparoscopic hernia surgery with
or without prosthetic material, diagnostic laparoscopy and excisional lymph node biopsy
High Strong against
For laparoscopic cholecystectomy surgery High Strong against
Intranasal mupirocin in adult patients undergoing surgery with a high risk of major morbidity due
to S. aureus or MRSA
High Strong for
For craniotomy and cerebrospinal flow deviation High Strong for
For induction of abortion and cesarean section High Strong for
For abdominal and vaginal hysterectomy Moderate Strong for
For salpingo-oophorectomy and ovarian tissue excision or reconstruction High Strong against
For ankle prosthesis implantation High Strong for
For knee prosthesis implantation Low Strong for
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For closed fracture fixation, mounting a prosthetic device when there is no direct evidence
available, ankle fracture repair
High Strong for
For spinal surgery Moderate Strong for
For elective orthopedic surgeries without use of prosthesis Very low Strong against
For transurethral resection of the prostate, lithotripsy High Strong for
For transrectal prostate biopsy, radical prostatectomy, radical cystectomy, surgery of renal
parenchyma, nephrectomy and removal of hydrocele
Moderate Strong for
For transurethral resection of bladder tumors Very low Strong against
For lower limb amputation and arterial surgery in the abdomen or lower extremities Moderate Strong for
For carotidal thromboendarterectomy, endarterectomy, tubal surgery varicose veins and other
venous occlusions
Very low Strong against
Antibiotic must have a spectrum of action against likely contaminants Very low Weak for
Avoid beta-lactam antibiotics in patients with a history of anaphylaxis, urticaria, or rash
appearing immediately after treatment with penicillin
Low Weak for
Antibiotic prophylaxis should begin immediately before anesthesia and, in any case, of 30 to
60 min before the first skin incision
High Strong for
More than single antibiotic dose (except in special situations) Very low Strong against
Additional intraoperative dose of antibiotic in adults, to be held after the fluid replenishment, if a
loss of more than 1500ml of blood is verified during the operation or after hemodilution of
more 15 ml per kg
Very low Weak for
Consider the increased risk clostridium difficile infection associated with some antibiotics like
cephalosporins, clindamycin, fluoroquinolones, carbapenems
Low Weak for
Consider glycopeptides for prophylaxis in patients undergoing high-risk surgery that are positive for MRSA High Strong for
Registering a minimum set of data on medical history and treatment forms to assess the suitability
of perioperative antibiotic prophylaxis
Very low Strong for
7. Preanesthetic medication
Benzodiazepines Moderate Weak against
8. Thromboprophylaxis
Compression stockings High Strong for
Low molecular weight heparin
Continuation of contraceptives
9. Surgical site preparation
Alcohol-chlorhexidine use High Strong for
Antimicrobial agents (i.e., ointments, solutions, or powders) for prevention of surgical site infection Low Strong against
Hair clipping High Strong for
Adhesive strips of plastic with or without antimicrobial properties Moderate Weak against
Microbial sealant after intraoperative skin preparation Low Weak against
Patients bath with antiseptic agent at least one night before surgery Moderate Strong for
10. Prokinetic
For obstetrical patients Moderate Strong for
For non-obstetrical patients Moderate Strong against
Specific recommendations by some clinical specialties
Renal recommendation
11. Adjustments of insulin therapy in diabetic patients
50% reduction in long-acting insulin Low Strong for
Correction with short-acting insulin Low Strong for
Oral hypoglycemic agents Low Strong for
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population or the type of surgery. Out of these recom-
mendations, there were 28 (35.9%) with a high evidence
level, 18 (23.1%) with a moderate level, 24 (30.8%) with a
low level, and 8 (10.2%) with a very low level. Regarding
their recommendation strengths, 41 (52.6%) were strong
for, 18 (23.1%) were strong against, 14 (17.9%) weak for,
and 5 (6.4%) weak against. In Online supplemental
material Appendix 7, we present an additional table con-
cerning antimicrobial prophylaxis recommendations for
each surgical site.
We found discrepancies among EB-CPG in 3 out of 78
(4%) of the therapeutic/preventive care recommendations.
After applying the direction and strength of recommenda-
tions rule to decide doing or not doing the CPG, 15 (55
specific) recommended and 10 (23 specific) did not recom-
mended therapeutic/preventive interventions (see Online
supplemental material Appendix 8, Online supplemental
material Appendix 6 – Table 1 GRADE level of evidence
and strength of recommendations by CPG; Table 2 Recom-
mended therapeutic/preventive care only, and Table 3 Not
recommended therapeutic/preventive care).
Discussion
To the best of our knowledge, the present study is the
first overview of guidelines encompassing a broad
spectrum of preoperative care recommendations.
We observed higher level of evidence supporting thera-
peutic than risk stratification recommendations (high/
moderate quality of evidence 59 vs 22%, respectively). It is
not surprising because cross-sectional or cohort studies
can provide high-quality evidence for test accuracy but in-
direct evidence for patient-important outcomes. Further-
more, highs level of heterogeneity is almost the rule in
risk stratifications test, downgrading even more the level
of evidence because of inconsistency [42–44].
The strength of a recommendation is defined as the
extent to which one can be confident that the desirable
effects of an intervention outweigh its undesirable ones.
We found only 12/53 (23%) “strong” risk stratification
recommendations statements (for and against) based on
high/moderate level of evidence and 43/78 (55%) for
therapeutic/preventive care recommendation. Although
it would be desirable that higher proportions of high-







Continuation of beta-blockers Low Weak for
For patients with positive test for myocardial ischemia undergoing vascular surgery Low Weak for
Start the day of surgery treatment regardless of the condition to be treated High Strong against
13. Statins
Continuation of statins or start before undergoing noncardiac surgery patients with significant
atherosclerosis as secondary prevention
Low Weak for
Treatment naïve patients undergoing noncardiac surgery without significant atherosclerosis Low Strong against
14. Aspirin
Suspending aspirin three or more days before noncardiac surgery and not restart within a week after it High Strong for
Continuation of aspirin (75–100mg daily) in patients who presented acute coronary syndrome in the
last 12 months or history of percutaneous coronary intervention
Low Weak for
Start or not to suspend treatment prior to surgery High Strong against
15. Renin-angiotensin system inhibitors
Suspend them the day of surgery in chronically medicated patients and restart immediately in
hemodynamically stable conditions
Low Weak for
Start in patients with severe hypertension or ventricular dysfunction if suspending the day of surgery
Start treatment the day of surgery in patients who do not receive it chronically Low Strong against
16. Calcium channel blockers
Suspend the single preoperative dose the day of the surgery in chronically medicated patients Low Weak for
Starting treatment in patients with inducible myocardial ischemia or suspected coronary vasospasm
during preoperative evaluation and suspend the single dose the day of surgery
Starting calcium channel blockers in the preoperative surgery in patients who do not receive chronically Low Strong against
MRSA methicillin resistant Staphylococcus aureus
*The presented level of evidence and recommendation strength comes from the EB-CPG with the highest overall and methodological rigor AGREE-II score. The
level of evidence and recommendation strength by EB-CPG are presented in the online supplemental material 8.a
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quality supporting evidence guide panel must consider
additional factors. In order to assess competing man-
agement alternatives, GRADE proposes to consider
four domains: estimates of effect for desirable and
undesirable outcomes, confidence in the estimates of
effect, values and preferences, and resource use.
Guideline panels must integrate these factors to make
a strong or weak recommendation for or against an
intervention [45].
After our search date, the updated guideline from the
European Society of Anesthesiology (ESA) was published,
using GRADE and searching until May 2016 [46]. This
CPG addressed two main clinical questions in order to
help each anesthesiologists in their daily practice: (1) how
should a pre-operative consultation clinic be organized
and (2) how should pre-operative assessment of a patient
be performed. As in our present work, this guideline cov-
ered specific conditions that might adversely interfere with
anesthesia and surgery, including cardiovascular disease,
respiratory disease, smoking, obstructive sleep apnea syn-
drome, renal disease, diabetes, obesity, coagulation disor-
ders, anemia and pre-operative blood conservation
strategies, the geriatric patient, alcohol and drug misuse
and addiction, and currently also neuromuscular disease.
We are hereby presenting a preoperative clinical risk
criteria and categories that were complemented with
established risk factors for postoperative pulmonary com-
plications (see Online supplemental material Appendix 3)
[46]. The 2018 ESA guidelines also provided independent
predictors for difficult mask ventilation, a topic not specif-
ically addressed in previous CPGs [46].
As described, RCTs are still few and therefore many
preoperative interventions rely to a large extent on expert
opinion, which in turn requires to be adapted to the reality
of nations’ healthcare systems. This large evidence gap
should be addressed by related researchers in order to im-
prove the certainty in evidence-based recommendations.
Studies on prognostic or diagnostic accuracy tests, in-
cluding scoring of severity of illness, usually provide low
quality of evidence, even when scores such as ASA-PS,
RCRI, NSQIP-MICA, POSSUM, and others have been
extensively validated [46].
Our updated overview of EB-CPGs, conducted under
the rigorous Cochrane methods, may be a useful resource
for the professionals involved in preoperative care to con-
sult during decision-making. We present many strong rec-
ommendations with sufficient evidence to be routinely
implemented in clinical practice. However, any decision
should be taken considering local contextual factors.
In addition, cost reductions were identified at the clin-
ical level as well as at the health system level in another
study [10–12, 47]. Two guidelines also suggested strong
costs benefits both for patients and society [48, 49]. An-
other study showed that the application of EB-CPGs
significantly improved the efficiency of the preoperative
evaluation without negatively affecting the quality of care
[50]. These findings were consistent across different set-
tings, like in a hospital in Barbados where the introduction
of guidelines reduced the burden of presurgical tests and
costs with not hampering patient’s safety [51]. In the same
way, a recent study in a hospital in New Jersey, USA,
found that approximately 25% of tests were not justifiable
and could be thus eliminated by complying with NICE/
ASA guidelines. The evaluation of applying these changes
in practice showed significant savings without altering
clinical outcomes [52].
Recommendations can be adopted, modified, or even
not implemented, depending on institutional or national
requirements and legislation and local availability of de-
vices, drugs, and resources [53]. Decision-makers at the
national and subnational levels should be provided with
the information they need to apply the evidence and rec-
ommendations in their setting [54]. As a limitation, in-
cluding only EB-CPGs could have resulted in omitting
some information, but we prioritized summarizing the
highest quality evidence. Our exclusion criteria for
CPGs, limiting the scope, may represent an additional
caveat. Our inclusion/exclusion criteria focused on gen-
eral recommendations provided a lower amount of evi-
dence for certain practices than if we had also included
recommendations for single conditions, specific prophy-
laxis, or single body part surgeries. Such approach, how-
ever, would have compromised the feasibility of our
systematic review due to the enormous number of such
guidelines. Nonetheless, we provided detailed lists with
numerous recommendations and reflected guideline’s
discrepancies, suggesting that this could not have been a
major limitation.
Our study will be useful for future preoperative care
guideline developers or adapters. Consistently with other
overviews of clinical guidelines, the domain that received
the lowest mean score was the “applicability” domain of
the AGREE-II tool. Similarly, the heterogeneity of evi-
dence and the strength of recommendation grading sys-
tems in this overview echo that of other clinical
guideline overviews [55–57]. Low scores in the applic-
ability domain result in inadequate adoption rates of
guidelines, particularly for preoperative care where “de-
fensive medicine” (i.e., prescribing more tests than ne-
cessary just to prevent litigation) is very common. We
also found some discrepancies, mainly in the evidence
level, in each recommendation that did not always dis-
criminate between universal interventions and those suit-
able only for special target groups or specific surgeries.
Guideline developers should ensure rigorous methodo-
logical processes and should also make recommendations
that are formulated and disseminated in ways that facilitate
understanding and application by end-users. For example,
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the DECIDE Collaboration conducted research and devel-
oped tools to improve implementation of evidence-based
recommendations by different target audiences, including
providers, policy makers, and the public [58]. In that sense,
GRADE provides guideline developers with a comprehen-
sive and transparent framework for grading quality of
evidence and of strength of recommendations.
Our overview identified several controversies, evidence
gaps, and issues regarding preoperative care guidelines
that warrant future research and reveal opportunities to
improve the guidelines quality.
For example, we found many discrepancies about risk
stratification recommendations like electrocardiography and
chest X-ray, polysomnography, assessment of left ventricular
function, stress testing, and coronary angiography in certain
populations. We found less discrepancies for therapeutic/
preventive care mainly because antimicrobial prophylaxis
use beta-blockers (find these discrepancies in the Online
supplemental material Appendix 6 and Appendix 8).
From the perspective of the anesthesiologist practice,
there still remain many unanswered questions. For
example, in the patient with significant medical, surgical,
or obstetrical history, it would be useful to understand
how early the pre-anesthetic evaluation should be
performed, considering the time required to optimize
the patient’s status. There are also uncertainties for the
recommendation of fasting for solids in adults and
children since many factors can delay gastric emptying,
and no fixed rules apply. Fasting should be individual-
ized in some patients and depend on the characteris-
tics of the fat intake. Regarding prokinetics and
antacids, patients’ comorbidities like esophageal path-
ology, bariatric surgery history, or obesity should be con-
sidered in the decision, but there is no formal
recommendation. In the same way, suspending or not
suspending aspirin should be evaluated according to the
patient’s history and risk of bleeding of the surgery that
could be catastrophic in neurosurgery, spinal surgery, or
ophthalmologic surgery. It is also strange that informed
consent only has a “weak for,” recommendation from a
unique CPGs since there is enough background of
litigation due to the lack of consent.
We encourage guideline developers to adopt GRADE
and AGREE-II tools to elaborate future sound preopera-
tive care guidelines [7, 22].
The huge amount of resources involving preoperative
care warrants high-quality nationwide EB-CPGs sup-
ported by all relevant stakeholders to improve the chances
of a successful implementation. This probably includes
the involvement of the Ministry of Health, scientific soci-
eties, and consumers working together through a formal
process of implementation and monitoring [17, 59].
Although standardization of preoperative care may be
desirable, differences in recommendations could reflect
differences in contextual factors such as organizational or
financial arrangements, legal framework, varied values and
preferences, and the acceptability and feasibility of using
different interventions. Research exploring reasons for
conflicting recommendations in different countries or set-
tings could also drive overall improvements in guideline
quality. The key findings are described in Table 4.
In conclusion we found significant heterogeneity of
guidelines’ quality and rating systems, as well as deficien-
cies in several guideline quality domains, which reveal
opportunities for quality improvement which deserve
careful consideration by future guideline developers.
Nevertheless, we present many strong recommendations
ready to be at present considered for implementation or
discontinuation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-01404-8.
Additional file 1. Online Only Supplemental Material.
Abbreviations
CPG: Clinical practice guidelines; GRADE: Grading of Recommendations
Assessment, Development, and Evaluation; HTA: Health Technology
Assessment; EB-CPG: Evidence based-clinical practice guidelines;
RCT: Randomized clinical trials; Y: Yes; N: No; PY: Probably yes; PN: Probably
no; HSTAT: Health services/technology assessment text; NICE: National
Institute for Health and Clinical Excellence; ICSI: Institute for Clinical Systems
Improvement; ESA: European Society of Anesthesiology; ESC/ESA: European
Society of Cardiology/European Society of Anesthesia; SBC: Brazilian Society
of Cardiology; ACC/AHA: American College of Cardiology/American Heart
Association; CCSG: Canadian Cardiovascular Society; SARNePI: Italian Society
of Anesthesia and Intensive Pediatric Therapy and Neonatology; ICSI: Institute
for the Improvement of Clinical Systems; BARA: Regional Anesthesia
Associations of Belgium; ASHP: American Society of Health-System Pharma-
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Table 4 Key points
• The included evidence-based clinical practice guidelines (EB-CPGs)
showed significant heterogeneity both of evidence and recommenda-
tion grading systems; GRADE was the most commonly used.
• About half of the included EB-CPGs were updated in the last 5 years,
and one third of them were rated as strongly recommended based in
their high AGREE-II performance.
• They were generally deficient in applicability and in providing
monitoring tools.
• We summarized 31 risk stratification and 16 therapeutic/preventive
recommendations.
• We found 93 strong for and 46 strong against recommendations, all of
which were ready to be considered to be implemented or to be
interrupted, respectively.
• The level of evidence and strength of recommendation was higher for
therapeutic/preventive recommendation than for risk stratification
ones.
• We only found 12/53 (55%) strong risk stratification recommendations
based on high/moderate level of evidence and 43/78 (55%) for
therapeutic/preventive care recommendations.
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